LinkOPH

SAN DIEGO — The substantial incidence of asymptomatic choroidal neovascularization in the fellow eye of patients with neovascular age-related macular degeneration warrants bilateral complete retinal examination of all such patients at each visit, according to a presenter here. Abdhish R. Bhavsar, MD, and colleagues found that in a single-surgeon series of 803 consecutive patients with neovascular AMD, CNV developed in the asymptomatic fellow eye of 50 patients (6.2%). Median age at initial presentation for treatment of the primary eye was 76 years; median age at diagnosis of CNV in the (Read more...)

Despite extensive advances in the management of retinal detachment (RD) over the past 40 years, RD repair continues to further evolve and improve.As Dr. Patrick Williams notes in this column, the ASRS PAT Survey shows a decline over the past decade in …

Read more →

At the end of the Algerian war, in 1962, there were only five ophthalmologists in the whole country. Since then, Algeria has gone through a large reorganization, established a national health care system and greatly increased human resources in all branches of medicine.“We are now 1,500 ophthalmologists, which is undoubtedly a great progress. Nevertheless, this number is not yet sufficient to serve a population of 38 million. We are far from covering the needs of our patients,” Boualem Chachoua, MD, president of the national association of private ophthalmologists, said.

Read (Read more...)

Genentech has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration for Lucentis for the treatment of diabetic retinopathy. “Diabetic retinopathy is the leading cause of new blindness in working-aged Americans. Our hope is that having Lucentis approved as the first ocular treatment for diabetic retinopathy in the U.S. will have a positive impact on patients who have diabetic retinopathy,” Jason Ehrlich, MD, PhD, Genentech group medical director, said in an interview with Ocular Surgery News.

Read more →